CN107635992B - 用作tnf抑制剂的三环杂环化合物 - Google Patents

用作tnf抑制剂的三环杂环化合物 Download PDF

Info

Publication number
CN107635992B
CN107635992B CN201680025154.3A CN201680025154A CN107635992B CN 107635992 B CN107635992 B CN 107635992B CN 201680025154 A CN201680025154 A CN 201680025154A CN 107635992 B CN107635992 B CN 107635992B
Authority
CN
China
Prior art keywords
phenyl
imidazo
pyridazin
difluoromethoxy
tetrahydropyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680025154.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107635992A (zh
Inventor
S·T·弗罗布莱斯基
G·D·布朗
S·林
J·端
Z·鲁
T·G·M·达尔
H·肖
A·J·泰本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN107635992A publication Critical patent/CN107635992A/zh
Application granted granted Critical
Publication of CN107635992B publication Critical patent/CN107635992B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201680025154.3A 2015-03-18 2016-03-17 用作tnf抑制剂的三环杂环化合物 Active CN107635992B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562134779P 2015-03-18 2015-03-18
US62/134,779 2015-03-18
PCT/US2016/022738 WO2016149437A1 (en) 2015-03-18 2016-03-17 Tricyclic heterocyclic compounds useful as inhibitors of tnf

Publications (2)

Publication Number Publication Date
CN107635992A CN107635992A (zh) 2018-01-26
CN107635992B true CN107635992B (zh) 2020-05-22

Family

ID=55640933

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680025154.3A Active CN107635992B (zh) 2015-03-18 2016-03-17 用作tnf抑制剂的三环杂环化合物

Country Status (14)

Country Link
US (1) US10308652B2 (enExample)
EP (1) EP3271361B1 (enExample)
JP (1) JP6793658B2 (enExample)
KR (1) KR102630010B1 (enExample)
CN (1) CN107635992B (enExample)
AU (1) AU2016233289A1 (enExample)
BR (1) BR112017019731A2 (enExample)
CA (1) CA2982446A1 (enExample)
EA (1) EA032314B1 (enExample)
ES (1) ES2797685T3 (enExample)
IL (1) IL254520A0 (enExample)
MX (1) MX2017011433A (enExample)
SG (1) SG11201707471RA (enExample)
WO (1) WO2016149437A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2803650T3 (es) 2015-03-18 2021-01-28 Bristol Myers Squibb Co Compuestos heterocíclicos útiles como inhibidores de TNF
ES2797805T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos sustituidos
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
UY36630A (es) 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
EP3331889B1 (en) 2015-08-03 2020-09-23 Bristol-Myers Squibb Company Cyclic compounds useful as modulators of tnf alpha
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP3596078B1 (en) 2017-03-15 2023-04-12 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391806A (en) * 1982-07-12 1983-07-05 The Dow Chemical Company Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators
WO2014009295A1 (en) * 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE238998T1 (de) 1997-02-25 2003-05-15 Us Gov Health & Human Serv Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
AU7922900A (en) * 1999-10-27 2001-05-08 Novartis Ag Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
EP1479681A4 (en) 2002-01-31 2006-05-10 Daiichi Seiyaku Co IMIDAZO (1,2-a) pyridine
WO2004050035A2 (en) 2002-12-03 2004-06-17 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
WO2009045174A1 (en) 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
CA2874303C (en) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
MX2015005375A (es) * 2012-11-07 2015-07-21 Hoffmann La Roche Compuestos de triazolo.
ES2529865B8 (es) * 2013-07-25 2016-01-22 Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz (Fibhulp) USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
EP3080085B1 (en) 2013-12-09 2019-08-14 UCB Biopharma SPRL Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015086519A1 (en) 2013-12-09 2015-06-18 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of tnf activity
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
KR20230035424A (ko) 2014-10-06 2023-03-13 시그날 파마소티칼 엘엘씨 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
ES2797805T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos sustituidos
ES2803650T3 (es) 2015-03-18 2021-01-28 Bristol Myers Squibb Co Compuestos heterocíclicos útiles como inhibidores de TNF
UY36630A (es) * 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
EP3292127A1 (en) * 2015-05-04 2018-03-14 Actelion Pharmaceuticals Ltd Tricyclic piperidine compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391806A (en) * 1982-07-12 1983-07-05 The Dow Chemical Company Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators
WO2014009295A1 (en) * 2012-07-13 2014-01-16 Ucb Pharma S.A. Imidazopyridine derivatives as modulators of tnf activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"A Flexible Three-Component Synthesis of Novel d-Amino Acids Incorporating an Imidazo[1,2-a]pyridine Backbone";Ivana Veljkovic et al.;《SYNTHESIS》;20060719(第16期);第2677-2684页 *
"Efficient preparation of imidazo[1,2-b]pyridazines under Swern oxidative conditions";Pierre Raboisson et al.;《Tetrahedron Letters》;20031231;第44卷;第2919–2921页 *
"Synthesis of C8-C9 Annulated Purines by Iron-Catalyzed C-H Amination";Jens Maes et al.;《Chem. Eur. J.》;20130603;第19卷;第9137-9141页 *
Vikas Chaudhary et al.."Scaffold-hopping and hybridization based design and building block strategic synthesis of pyridine-annulated purines: discovery of novel apoptotic anticancer agents".《RSC Advances》.2015,第5卷第26051–26060页. *

Also Published As

Publication number Publication date
JP6793658B2 (ja) 2020-12-02
SG11201707471RA (en) 2017-10-30
EP3271361A1 (en) 2018-01-24
ES2797685T3 (es) 2020-12-03
EA032314B1 (ru) 2019-05-31
JP2018508554A (ja) 2018-03-29
KR20170129811A (ko) 2017-11-27
MX2017011433A (es) 2017-11-10
IL254520A0 (en) 2017-11-30
CA2982446A1 (en) 2016-09-22
CN107635992A (zh) 2018-01-26
AU2016233289A1 (en) 2017-11-09
WO2016149437A1 (en) 2016-09-22
US20180111937A1 (en) 2018-04-26
EA201792025A1 (ru) 2018-01-31
US10308652B2 (en) 2019-06-04
KR102630010B1 (ko) 2024-01-25
EP3271361B1 (en) 2020-04-22
BR112017019731A2 (pt) 2018-05-22

Similar Documents

Publication Publication Date Title
US10308652B2 (en) Tricyclic heterocyclic compounds useful as inhibitors of TNF
JP7083358B2 (ja) Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
CN108137547B (zh) 可用作TNFα调节剂的杂环化合物
WO2021057882A1 (zh) Egfr抑制剂、组合物及其制备方法
JP6779899B2 (ja) Ｔｎｆ阻害剤として有用なヘテロ環式化合物
CN108137609B (zh) 用作TNFα的调节剂的环状化合物
CN107635993B (zh) 取代的三环杂环化合物
CN107108555B (zh) 三环阻转异构体化合物
CN107148409A (zh) 经取代的二环化合物
TW202333678A (zh) 一種磺醯脲類化合物
CN112574212B (zh) 一种嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
WO2026012376A1 (zh) 趋化因子受体调节剂制备方法和用途
WO2026092659A1 (zh) 一种多环类化合物及其制备方法和应用
HK40061670A (en) Compounds and compositions for treating conditions associated with apj receptor activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant